A Phase 1/2 interventional study of 100 million Allogeneic Mesenchymal Human Stem Cells and Placebo in Diabetes Mellitus and Ischemic Heart Disease, sponsored by Joshua M Hare. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Joshua M Hare · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 1,906th largest by enrollment of the 2,502 interventional ones that give a count, is one of 113 that started in 2021, is one of 58 in phase 1/2, and was the 2,475th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,023 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 113 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,502 interventional studies, 159 across the 499 observational. Of the 2,399 that completed or were terminated, 991 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,023 have an industry lead sponsor. The 10 most frequent:
Joshua M Hare is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Joshua M Hare has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
Drug: 100 million Allogeneic Mesenchymal Human Stem Cells
Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
Other: Placebo
1 single intravenous infusion
Also known as: allo-human Mesenchymal Stem Cells (hMSCs), stem cells
Placebo delivered via peripheral intravenous infusion
Brachial Artery Flow Mediated Diameter Percentage (FMD%)
FMD% is measured via brachial artery ultrasound. The unit of measure is percent.
Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6
EPC-CFU Counts
Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples. The unit of measure is the average number of colonies per well.
Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6
Fractional Flow Reserve (FFR)
Fractional Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.
Time frame: Baseline, Month 6
Coronary Flow Reserve (CFR)
Coronary Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.
Time frame: Baseline, Month 6
Seattle Angina Questionnaire (SAQ) Angina Frequency (AF)
SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.
Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6
Seattle Angina Questionnaire (SAQ) Quality of Life (QL)
SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.
Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6
Number of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE)
TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 30 sec or with hemodynamic compromise) or atrial fibrillation at 1 month post-infusion. TE-SAEs will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.
Time frame: 1 month post infusion
Number of Participants With Major Adverse Cardiac Events (MACE)
Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal myocardial infarction MI at 1 year. MACE will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.
Time frame: 12 months
Number of Participants With Target Vessel Failure
Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI (percutaneous coronary intervention). The unit of measure is number of participants.
Time frame: 12 months
Number of Participants With Treatment Emergent Adverse Events
The number of participants who experienced a Treatment Emergent Adverse Event (AE), as assessed by study physician, will be reported. The unit of measurement is the number of participants who experienced an event.
Time frame: 12 months
Number of Participants With Abnormal Lab Values
Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician. The unit of measure is number of participants.
Time frame: 12 months
Circulating Angiogenic Marker - VEGF
Vascular Endothelial Growth Factor (VEGF) levels from serum samples. Results are provided in units of pg/mL. Higher levels of VEGF are associated with better cardiovascular health.
Time frame: Baseline, Month 1, Month 3, Month 6
Circulating Cytokine Biomarker - TNFα
Circulating Tumor necrosis factor alpha (TNFα) levels from serum samples. Results are provided in units of pg/mL. Lower values are associated with reduced inflammation.
Time frame: Baseline, Month 1, Month 3, Month 6
| Milestone | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Started | 13 | 13 |
| Completed | 12 | 12 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
FMD% is measured via brachial artery ultrasound. The unit of measure is percent.
| percentage | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 5.80 ± 3.46 | 4.28 ± 2.10 |
| Week 2 | 6.98 ± 3.39 | 5.93 ± 3.13 |
| Month 1 | 7.19 ± 2.84 | 5.64 ± 2.65 |
| Month 3 | 7.48 ± 3.59 | 6.20 ± 2.94 |
| Month 6 | 7.2 ± 2.93 | 5.62 ± 1.79 |
Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples. The unit of measure is the average number of colonies per well.
| CFUs per well | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 4.92 (1.42 to 7.38) | 8.67 (7.33 to 12.33) |
| Week 2 | 12.16 (4.46 to 17.7) | 11.67 (10.67 to 12.5) |
| Month 1 | 11.34 (4.59 to 15.75) | 10.75 (5.17 to 14.83) |
| Month 3 | 7.83 (7 to 9.16) | 28.5 (3.17 to 31) |
| Month 6 | 3.5 (0.33 to 12.7) | 20.83 (4.33 to 33.5) |
Fractional Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.
| ratio | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 0.83 ± 0.24 | 0.9 ± 0.07 |
| Month 6 | 0.9 ± 0.06 | 0.86 ± 0.08 |
Coronary Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.
| ratio | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 2.82 ± 1.22 | 2.64 ± 1.78 |
| Month 6 | 2.55 ± 1.9 | 3.78 ± 2.99 |
SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.
| score on a scale | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 76.15 ± 33.55 | 84.62 ± 25.04 |
| Week 2 | 87.5 ± 24.54 | 90.77 ± 11.88 |
| Month 1 | 90 ± 17.32 | 94.62 ± 9.67 |
| Month 3 | 86.67 ± 25.35 | 95.38 ± 9.67 |
| Month 6 | 90 ± 20 | 95.83 ± 11.65 |
SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.
| score on a scale | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Baseline | 53.85 ± 35.5 | 54.81 ± 24.76 |
| Week 2 | 69.79 ± 23.51 | 70.19 ± 29.11 |
| Month 1 | 73.08 ± 22.73 | 63.46 ± 25.24 |
| Month 3 | 71.88 ± 27.76 | 82.69 ± 26.29 |
| Month 6 | 72.92 ± 27.61 | 65.63 ± 32.48 |
TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 30 sec or with hemodynamic compromise) or atrial fibrillation at 1 month post-infusion. TE-SAEs will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.
| Participants | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Number of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE) | 2 | 1 |
Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal myocardial infarction MI at 1 year. MACE will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.
| Participants | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Number of Participants With Major Adverse Cardiac Events (MACE) | 2 | 3 |
Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI (percutaneous coronary intervention). The unit of measure is number of participants.
| Participants | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Number of Participants With Target Vessel Failure | 0 | 2 |
The number of participants who experienced a Treatment Emergent Adverse Event (AE), as assessed by study physician, will be reported. The unit of measurement is the number of participants who experienced an event.
| Participants | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 2 | 1 |
Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician. The unit of measure is number of participants.
| Participants | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Number of Participants With Abnormal Lab Values | 1 | 4 |
Vascular Endothelial Growth Factor (VEGF) levels from serum samples. Results are provided in units of pg/mL. Higher levels of VEGF are associated with better cardiovascular health.
| pg/mL | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| VEGF Baseline | 1,169.62 ± 379.73 | 1,303.36 ± 604.34 |
| VEGF Month 1 | 1,220.7 ± 380.24 | 1251.62 ± 588.55 |
| VEGF Month 3 | 1243.28 ± 432.1 | 1173.4 ± 469.88 |
| VEGF Month 6 | 1057.23 ± 425.58 | 1234.75 ± 566.07 |
Circulating Tumor necrosis factor alpha (TNFα) levels from serum samples. Results are provided in units of pg/mL. Lower values are associated with reduced inflammation.
| pg/mL | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| TNFα - Baseline | 14.70 ± 4.49 | 13.02 ± 2.96 |
| TNFα - Month 1 | 14.50 ± 5.51 | 12.90 ± 2.99 |
| TNFα - Month 3 | 12.54 ± 2.23 | 14.09 ± 5.08 |
| TNFα - Month 6 | 15.53 ± 7.90 | 18.36 ± 14.68 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Group B: Placebo Group | 0/13 (0%) | 4/13 (30.8%) | 9/13 (69.2%) |
| Event | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Increased CreatinineInvestigations | 0/13 | 2/13 |
| Atrial FibrillationCardiac disorders | 0/13 | 1/13 |
| Acute Coronary SyndromeCardiac disorders | 1/13 | 0/13 |
| Cardiac Chest PainCardiac disorders | 1/13 | 1/13 |
| Heart Failure ExacerbationCardiac disorders | 1/13 | 0/13 |
| Non-Cardiac Chest PainGeneral disorders | 1/13 | 0/13 |
| Lung InfectionInfections and infestations | 0/13 | 1/13 |
| FallInjury, poisoning and procedural complications | 1/13 | 0/13 |
| Carotid Artery InjuryInjury, poisoning and procedural complications | 1/13 | 0/13 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/13 | 1/13 |
| Event | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group |
|---|---|---|
| Cardiac Chest PainCardiac disorders | 3/13 | 1/13 |
| AnemiaBlood and lymphatic system disorders | 2/13 | 0/13 |
| Heart Failiure ExacerbationCardiac disorders | 0/13 | 2/13 |
| In stent re-stenosisCardiac disorders | 0/13 | 2/13 |
| Lung InfectionInfections and infestations | 0/13 | 2/13 |
| DizzinessNervous system disorders | 0/13 | 2/13 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/13 | 0/13 |
| Bilateral Axillary AdenopathyBlood and lymphatic system disorders | 1/13 | 0/13 |
| Atrial FlutterCardiac disorders | 1/13 | 0/13 |
| PalpitationsCardiac disorders | 1/13 | 0/13 |
| Age, Continuous(years) | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group | Total |
|---|---|---|---|
| Mean | 63.85 ± 6.47 | 62.62 ± 10.99 | 63.23 ± 8.95 |
| Sex: Female, Male(Participants) | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 12 | 11 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 17 |
| Not Hispanic or Latino | 5 | 4 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group | Group B: Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 13 | 11 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Mar 2025, 43 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 40 phase 1/2 interventional studies under Diabetes Mellitus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 43 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem Cell
Joshua M Hare